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Abstract
We report on a newly discovered serum and cerebrospinal fluid (CSF) reactivity to Purkinje cells (PCs) associated
with subacute inflammatory cerebellar ataxia. The patient, a previously healthy 33-year-old lady, presented with
severe limb and gait ataxia, dysarthria, and diplopia two weeks after she had recovered from a common cold.
Immunohistochemical studies on mouse, rat, and monkey brain sections revealed binding of a high-titer (up to
1:10,000) IgG antibody to the cerebellar molecular layer, Purkinje cell (PC) layer, and white matter. The antibody is
highly specific for PCs and binds to the cytoplasm as well as to the inner side of the membrane of PC somata,
dendrites and axons. It is produced by B cell clones within the CNS, belongs to the IgG1 subclass, and activates
complement in vitro. Western blotting of primate cerebellum extract revealed binding of CSF and serum IgG to an
80-97 kDa protein. Extensive control studies were performed to rule out a broad panel of previously described
paraneoplastic and non-paraneoplastic antibodies known to be associated with cerebellar ataxia. Screening of
>9000 human full length proteins by means of a protein array and additional confirmatory experiments revealed
Rho GTPase activating protein 26 (ARHGAP26, GRAF, oligophrenin-1-like protein) as the target antigen. Preadsorp-
tion of the patient’s serum with human ARHGAP26 but not preadsorption with other proteins resulted in complete
loss of PC staining. Our findings suggest a role of autoimmunity against ARHGAP26 in the pathogenesis of suba-
cute inflammatory cerebellar ataxia, and extend the panel of diagnostic markers for this devastating disease.
Background
Autoimmune cerebellar ataxia (ACA) is an etiologically
and pathologically heterogeneous syndrome. Besides
multiple sclerosis (MS), paraneoplastic neurological dis-
orders (PND) are the most common cause of ACA[1,2].
Many cases of paraneoplastic ACA are associated with
serum or CSF antibodies to neuronal and/or glial anti-
gens such as anti-Hu[3], anti-Yo[4], anti-CV2/CRMP5
[5,6], anti-Tr[7], anti-Zic4[8], anti-protein kinase C
gamma (PKCg)[9], anti-mGluR1[10,11], anti-PCA2[12],
anti-ANNA3[13], or antibodies to voltage gated calcium
channels (VGCC)[14]. In patients with non-paraneoplas-
tic ACA, antibodies to glutamate decarboxylase[15,16],
tissue transglutaminase[17], glutamate receptor δ2
(GluRδ2)[18,19], and Homer-3[20] have been described.
Here we report a newly discovered autoantibody to
Purkinje cells in a patient with subacute cerebellar ataxia
but no tumor. This antibody binds specifically to the
inner membrane and cytoplasm of PC somata, dendrites
and axons. It is produced intrathecally, belongs to the
IgG1 subclass and activates complement in vitro. Prob-
ing of a protein microarray with the patient’s serum and
additional confirmatory experiments identified the Rho
GTPase activating protein 26 (ARHGAP26) as the target
antigen.
Case history
A 33-year-old Caucasian lady was admitted to our hos-
pital with a five-day history of diplopia, slurred speech,
and gait instability. Two weeks before onset of symp-
toms she had recovered from a common cold. Neurolo-
gic assessment revealed horizontal nystagmus,
dysarthria, limb ataxia predominantly affecting the right
upper extremity, and severe gait ataxia. Cranial and
spinal magnetic resonance imaging (MRI), ultrasound
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sensory evoked potentials asw e l la sn o c i c e p t i v eb l i n k
and trigeminal inhibition reflexes were normal. CSF ana-
lysis disclosed 44 lymphocytes/μl with few plasma cells,
mild blood/CSF barrier dysfunction, increased CSF
ratios of IgG and IgM, and CSF-restricted oligoclonal
bands (OCB). Serology and/or PCR were negative for
HSV1, HSV2, VZV, EBV, HHV6, enterovirus, arbovirus,
HBV, HCV, HIV, borrelia, treponema. Routine blood
analysis (including CRP, blood sedimentation rate, and
chromogranin A) was unremarkable except for a slightly
elevated titer of serum antinuclear antibodies (1:320).
No antibodies to extractable nuclear antigens were
detectable. Testing for anti-neutrophil cytoplasmic anti-
bodies was negative. The presumptive diagnosis was
postinfectious cerebellitis, and the patient was treated
with 3 × 1000 mg methylprednisolone (MP) intrave-
nously followed by oral therapy over three weeks at an
initial dose of 60 mg. The corticosteroid therapy
resulted in marked neurological improvement, but was
associated with restlessness, sleeplessness, depressed
mood, and suicidal thoughts. After tapering corticoster-
oids to 12.5 mg MP per day the patient experienced
worsening of symptoms together with an exaggerated
startle response. Clinical examination demonstrated
tetra-ataxia, severe gait ataxia, oscillopsia, and marked
dysarthria. Moreover, a brisk head retraction reflex was
noted. The CSF had a normal cell count and persistent
intrathecal IgG synthesis. Routine laboratory tests, a
broad panel of tumor markers, thyroid hormones, anti-
thyroid antibodies (anti-thyroglobulin, anti-thyroid
peroxidase, anti-TSH receptor), anti-cardiolipin, and
common anti-neuronal antibodies (anti-Hu, -Yo, -Ri,
-Ma/Ta, -CV2/CRMP5, -GAD, -amphiphysin) were nor-
mal or negative. Whole body positron emission tomo-
graphy (PET) scans three, six and 13 months after
onset, repeat computed tomography (CT) of the chest
and abdomen, abdominal ultrasound and gynecologic
examinations did not show evidence of cancer. Repeat
brain MRI was negative two months after onset, but dis-
closed cerebellar atrophy at month 4 (Figure 1). An
FDG-PET examination at month 6 revealed a relative
hypometabolism of the right cerebellar hemisphere. The
exaggerated startle response was stabilized by lorazepam
(0.5 mg/d). A further course of intravenous MP pulse
therapy (5 × 500 mg) followed by treatment with 3 × 30
g intravenous immunoglobulins (IVIG) did not promote
improvement of neurologic deficits significantly. The
cerebellar syndrome finally stabilized and improved fol-
lowing plasma exchange (two courses of 4 and 3 treat-
ments) and immunoadsorption (two courses of 5 and 6
treatments). At last evaluation, 16 months after onset,
the patient presented with cerebellar signs and hyperek-
plexia without further progression and without evidence
of an underlying malignancy. The study was approved
by the institutional Review Board of the Medical Faculty
of the University of Heidelberg and the patient gave
written informed consent.
Immunological evaluation
Methods
Immunohistochemistry (IHC)
IHC was performed on cryosections of adult mouse cer-
ebellum, cerebrum, and brain stem tissue (Euroimmun,
Luebeck, Germany), on cryosections of adult rhesus
monkey cerebellum, brain stem, cerebrum, hippocam-
pus, hypothalamus, peripheral nerve, and intestine tissue
(Euroimmun), and on cryosections of adult rat cerebel-
lum and brain stem (Zyagen, San Diego, CA). Mouse
and monkey tissue was provided unfixed as snap frozen
sections (4-6 μm) and was fixed with 10% formalin in
phosphate buffered saline (PBS) for 4 min before testing.
For production of rat sections, animals had been per-
fused with 4% paraformaldehyde (PFA), the brains
removed, immersed to the same fixative up to 12 hours,
cryoprotected with sucrose, frozen in OCT, and finally
sectioned at a thickness of 4-10 μm. For some experi-
ments, 0.125% triton-X or 1% 3- [(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate (CHAPS) in PBS
were applied to the sections for 4 min. Sections were
then washed in PBS, blocked with 10% goat serum or
with 10% donkey serum, with respect to the secondary
antibodies used, and, after three washes in chilled PBS,
incubated with patient serum for 1 hour or with various
commercial antibodies for three hours at room tempera-
ture (RT) or overnight at 4°C. Binding of human IgG,
IgA and IgM to CNS tissue was detected by use of poly-
clonal goat anti-human IgG antibodies conjugated to
fluorescein isothiocyanate (FITC) (Euroimmun), Alexa
Fluor® (AF) 488 (Invitrogen, Karlsruhe, Germany) or
AF568 (Invitrogen), polyclonal donkey anti-human IgG
antibodies labeled with Rhodamin Red-X (Dianova,
Hamburg, Germany), and polyclonal goat anti-human
IgM and anti-human IgA antibodies conjugated to FITC
(Euroimmun), respectively. Binding of the following
commercial antibodies was detected using goat anti-
rabbit IgG AF568 (1:200-1:300; Invitrogen), goat anti-
mouse IgG AF568 (1:100-1:400; Invitrogen), donkey
anti-chicken IgG Rhodamin-Red × (1:100-1:200; Dia-
nova), or donkey anti-goat IgG AF488 (1:200-1:400) as
secondary antibodies depending on the primary antibo-
dies employed and on further secondary antibodies used
in double labeling experiments: goat anti-Homer3 (1:50;
Santa Cruz, Heidelberg, Germany); rabbit anti-protein
kinase C gamma (PKCg) (1:50; Santa Cruz); mouse anti-
metabotropic glutamate receptor 1a (mGluR1a) (1:200-
1:300; BD Pharmingen, Heidelberg, Germany); rabbit
anti-glutamate receptor delta 2 (GluRδ2) (1:25-1:50;
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clone 3B3) (1:25-1:500; Millipore, Schwalbach, Ger-
many); rabbit anti-inositol-triphosphate receptor type I
(IP3RI) (1:200; Dianova); chicken anti-glial fibrillary
acidic protein (GFAP) (1:1000; Encor Biotechnology,
Gainesville, FL); rabbit anti-aquaporin4 (AQP4) (1:200;
Sigma Aldrich, Taufkirchen, Germany); mouse anti-cal-
bindin-D (1:50; Swant, Bellinzona, Switzerland); goat
anti-parvalbumin (1:50; Swant); and anti-Rho GTPase-
activating protein 26 (ARHGAP26) (1:75; Santa Cruz).
For selected experiments, the patient’sC S Fw a si n c u -
bated with 3 μg of the following recombinant human
proteins for 3 h at RT prior to testing: ARHGAP26
(Abnova, Taipei, Taiwan); IP3RI (Santa Cruz); and
AQP4 (Abcam); the sera were then centrifuged at
11,2000 rpm for 10 min and the supernatants incubated
with cerebellum sections as described above. Sections
were then mounted using glycerol standard immuno-
fluorescence mounting medium containing 4’,6-diami-
dino-2-phenylindole (DAPI) (1:1000) (Euroimmun) or
ProLong Gold antifade reagent (Invitrogen). Slides were
analyzed on a Nikon 90i upright fluorescence micro-
scope and a Nikon A1 confocal microscope (Nikon Ima-
ging Center, University of Heidelberg, Heidelberg,
Germany).
IgG subclass analysis
For evaluation of IgG subclasses, serum and CSF sam-
ples were tested by IHC on mouse cerebellum sections
as described above, with the following modifications
applied: unconjugated sheep anti-human IgG antibodies
specific for IgG subclasses 1 to 4 (Binding site,
Germany) were substituted for the FITC-labeled goat
anti-human IgG antibody, and AF568 labeled donkey
anti-sheep IgG (Invitrogen; absorbed against human
IgG) was used to detect the subclass specific antibodies.
Complement assay
For evaluation of complement activation, mouse cerebel-
lum sections were incubated with heat inactivated serum
samples (60 min at 56°C) from our patient or controls
1:5 dilution for 60 minutes at 37°C. After three washes
in chilled PBS, pooled fresh frozen serum from three
healthy donors was applied as a source of complement
at 1:5 dilution for 45 minutes at 37°C, followed by fixa-
tion with 10% formalin for 15 min on ice and incuba-
tion with CHAPS for 1 min. Sections were then blocked
with 10% heat inactivated goat serum for 60 min and
subsequently incubated with a polyclonal rabbit anti-
human C3c/C3b antibody at a dilution of 1:250 for 45
minutes at 4°C (Dako, Hamburg, Germany), or a rabbit
isotype control (ready for use; Zymed Laboratories, San
Francisco, California) on ice. Binding of the C3c/C3b
specific antibody was visualized using a goat anti-rabbit
IgG AF568 antibody (1:300; 45 min; Invitrogen). Sec-
tions were washed in chilled PBS between incubations
and prior to mounting.
Western blot
Serum and CSF samples were tested for the presence of
antibodies to cerebellar antigens by use of a commer-
cially available western blot assay (Euroimmun, Ger-
many). Briefly, ready-made nitrocellulose membranes
containing rhesus monkey full cerebellum extract were
blocked with a ready-made blocking buffer (Euroim-
mun) for 15 min, incubated overnight at 4°C with
diluted serum (1:25) or CSF (1:4) from the patient or
healthy controls, washed three times in diluted blocking
buffer, and finally visualized using an alkaline phospha-
tase labeled anti-human IgG antibody as conjugate and
BCIP (5-bromo-4-chloro-3’-indolyphosphate p-toluidine
salt) and NBT (nitro-blue tetrazolium chloride) as chro-
mogenes. The reaction of BCIP/NBT to 5-5’-dibromo-
Figure 1 Magnetic resonance imaging of the cerebellum demonstrating marked cerebellar atrophy over the course of disease but no
contrast enhancement. (A) T1-weighted sagittal sequence; image obtained at month 3 after onset. (B) Gadolinium-enhanced sagittal T1-
weighted sequence; image obtained at month 17. Note the widening of the cerebellar sulci and the fourth ventricle.
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after 10 min by application of ice cold ddH2O. Addi-
tional membrane stripes originating from the same blot
were incubated with goat anti-Homer3 (1:100), rabbit
anti-PKCg (1:75), mouse anti-mGluR1a (1:200), rabbit
anti-GluRδ2 (1:75), rabbit anti-IP3RI (1:500), rabbit anti-
coilin (Santa Cruz) (1:100), and rabbit anti-ARHGAP26
(Santa Cruz), respectively. Binding of these antibodies to
their respective antigens was visualized using the Odys-
see® Infrared Imaging System after application of goat
anti-rabbit IgG labeled with Infrared dye (IRdye) 800
(Rockland Immunochemicals, Gilbertsville, PA) or goat
anti-mouse AF688 (Invitrogen) as secondary antibodies
(1:5000). A batch-specific evaluation matrix provided by
the manufacturer was used to identify molecular weight
(MW) ranges for proteins detected by the patient’s
serum and CSF or either of the commercial antibodies
used. In addition, bands detected with well established
paraneoplastic antibodies( R i ,8 0 k D a ;Y o ,6 2a n d
34 kDa; Ri, 55 kDa; Hu, 38kDa) were used to further
define MW ranges.
Intrathecal antibody synthesis
Oligoclonal IgG bands were assessed by standard meth-
ods employing isoelectric focusing of serum and CSF at
equal concentrations and subsequent detection of IgG by
immunoblotting. Quantitative expressions of intrathecal
antibody synthesis were based on calculation of the CSF/
serum ratios of Purkinje cell specific IgG antibodies and
total IgG (QIgG [spec] = IgGspec [CSF]/IgGspec
[serum], and QIgG [total] = IgGtotal [CSF]/IgGtotal
[serum]) [21]. Antibody titers were determined semi-
quantitatively by indirect immunofluorescence on mouse
cerebellum sections as described above. Total IgG and
total albumin concentrations in serum and CSF were
determined nephelometrically (BN ProSpec, Dade Behr-
ing, Germany). The intrathecal synthesis of anti-Purkinje
cell antibodies was detected by calculation of the corre-
sponding antibody index (AI): AI = QIgG [spec]/QIgG
[total], if QIgG [total] < Qlim, and AI = QIgG [spec]/
Qlim, if QIgG [total] > Qlim[21]. The upper reference
range of QIgG [total], Qlim, was calculated according to
Reiber’s formula to correct for possible underestimation
of intrathecal specific synthe s i sd u et op o s s i b l eb l o o d -
CSF barrier disturbance[21]. AI values >4 were consid-
ered to be indicative of intrathecal anti-Purkinje cell IgG
production[22].
Testing for co-existing autoantibodies
Commercially available immunoblots were used to test
for antibodies to Hu, Yo, Ri, amphiphysin, glutamate
decarboxylase (GAD), CV2/CRMP5, Ma2/PNMA2,
GM1, GM2, GM3, GD1a, GD1b, GT1b, GQ1b, and
AMA-M2 according to the manufacturer’si n s t r u c t i o n s
(Euroimmun). ANAs were assessed by immunocyto-
chemistry on HEp2 cells and further characterized by
commercial immunoblots for the detection of antibodies
t on R N P / S m ,S m ,a n dS S - A ,R o - 5 2 ,S S - B ,S c l - 7 0 ,P M -
Scl, Jo-1, PCNA, double stranded DNA (dsDNA), cen-
tromer protein B (CEPB), nucleosomes, histones, and
ribosomale P proteins (Euroimmun), and by double-
staining of tissue sections with a rabbit polyclonal anti-
body to p80-coilin (Santa Cruz).
Protein array
A commercially available human protein microarray (Pro-
toarray v5.0; Invitrogen) spotted with >9000 human full
length-proteins purified from a baculovirus-based expres-
sion system was probed with the patient’s serum according
to the manufacturer’s instructions. Briefly, the array was
incubated with blocking buffer containing 50 nM HEPES,
pH 7.5, 200 nM NaCl, 0.08% triton X-100, 25% glycerol,
20 nm reduced glutathione, 1 nM DTT, and a commercial
synthetic block (Invitrogen) for 1 h at 4°C. After washing,
the array was incubated with the patient’ss e r u ma ta
1:1500 dilution in washing buffer containing PBS-0.1%
Tween and synthetic block. After more washing steps, a
goat anti-human IgG detection antibody labeled with
AF647 (final concentration, 1 μg/μl) (Invitrogen) was
applied for 90 min at 4°C. A Genepix™ 4000 B microarray
scanner and corresponding application software (Genepix,
Sunnyvale, CA) was used to scan the slide, and Protoarray
v5.0 Prospector software (Invitrogen) to analyze the raw
data.
Dot blot assay
Protran BA79 nitrocellulose membranes (0.1 μm)
(Whatman) were spotted with increasing dilutions (1:2,
1:4, 1:8, 1:16, 1:32) of a 0.14 μg/μl solution of human
full length ARHGAP26 (10 μl/spot) in 0.1% bovine
serum albumin (BSA). After drying, membranes were
blocked with 5% bovine serum albumin (BSA) in Tris-
buffered saline (TBS) for 1 h at RT, washed three times
in TBS with 0.05% Tween (TBS-T), and finally incu-
bated with a 1:20 or 1:200 dilution of the patient’s
serum in 0.1% BSA/TBS-T for 1 h at RT. A donkey
anti-human IgG antibody labeled with IRdye 700DX
(Rockland) was used to detect bound IgG. Stripes were
finally washed in TBS and analysed using an Odyssey™
fluorescence scanner (Licor, Lincoln, NE) and Odyssey™
2.0.40 application software (Licor). As controls, serum
samples from three healthy donors were tested in the
same run.
Mixed cerebellar cultures
Mixed cerebellar cultures were prepared as published
previously[23,24]. Briefly, newborn NMRI mice were
killed by decapitation. Cerebella were dissected in PBS,
and meninges were removed. Tissues were treated with
trypsin (1% in PBS; Worthington, Freehold, NJ) for 3
min at room temperature (RT). After replacing trypsin
with DNase (0.05% in BME; Worthington), cerebella
were triturated successively with three fire-polished
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trifuged and resuspended in PBS with DNase, and the
cell slurry was passed through a 40 μMn y l o nm e s hf i l -
ter. Cells were resuspended in serum containing med-
ium, incubated in uncoated Petri dishes for 30 min at
37°C to remove fibroblast contamination, and finally
plated on coverslips coated with 500 μg/ml poly-D-
lysine. Plated cells were allowed to attach overnight, and
then the medium was changed to complete serum-free
medium composed of BME, BSA (10 mg/ml; A-8806,
Sigma), glutamax (10 mM), glucose (32 mM), 1 nM
triiodothyronine (Sigma-Aldrich), penicillin-streptomy-
cin (29 U/ml each, Invitrogen) and Sigma I-1884 supple-
ment. Thereafter, medium was replaced every 3-4 d
during culture period of 14 days.
Immunocytochemistry
Purkinje cell cultures were fixed with 4% paraformalde-
hyde and 0.05% triton-X at RT for 30 min and immu-
nostained with the patient’s serum (1:1000) or a mouse
monoclonal antibody against calbindin D28k (1:500;
Sigma-Aldrich) followed by incubation with an AF488-
or AF555-labeled goat anti-mouse or goat anti-human
IgG antibody (1:1000; Invitrogen). Cells were then
photographed with an AxioCam digital camera (Zeiss,
Germany) on a Zeiss Axio Imager microscope (63×
objective).
Results
Detection of a Purkinje cell-specific antibody in the CSF
Immunohistochemistry on formalin-fixed frozen adult
mouse, monkey and rat tissue sections demonstrated
strong reactivity of CSF and serum to structures in the
molecular layer (ML), the Purkinje cell layer (PCL), and
the white matter (WM) of the cerebellum (Figure 2).
More detailed analysis at higher magnification revealed
binding of IgG to somata, dendritic trunks, dendritic
branches, and possibly dendritic spines of Purkinje cells
(PCs). In addition, axons in the WM were stained by
the patient’s CSF and serum. Specific binding to Pur-
kinje cells (PC) was indicated by morphology and con-
firmed by double labeling of PCs with the patient
antibody and an anti-calbindin antibody (Figure 3). Dou-
ble labeling with anti-GFAP and anti-AQP4 revealed no
binding of the patient antibody to astrocytes in the WM
and the granular layer (GL), or to Bergman glial cells in
the PCL and ML (Figure 4). Binding to the soma of
interneurons such as stellate cells, basket cells and Golgi
cells or to granular cells was excluded by double label-
ing with parvalbumin and the patient’sC S Fa n ds e r u m
(Figure 5). Testing of formalin-fixed tissue sections of
cerebral cortex and white matter, brain stem, hippocam-
pus, hypothalamus, peripheral nerve, and plexus myen-
tericus under identical conditions was negative except
for single cell somata in the brain stem and cerebral
white matter (not shown). We decided to refer to the
specific staining pattern described here as to anti-Ca
throughout the manuscript, following a widely accepted
convention to name newly described antibodies with
reference to the index patient.
The antibody is produced intrathecally
A titer of 1:2000 was found with the first CSF sample
obtained (taken five days after onset of symptoms). A
paired serum sample taken at the same time yielded a
titer of 1:6000. This corresponded to an anti-Ca index
of 68 when related to CSF and serum albumin (Qlim;
see method section) in the same samples (Table 1), indi-
cating autochthonous production of the antibody within
the CSF. Intrathecal production of total IgG was further
indicated by the presence of CSF-restricted oligoclonal
bands and an increase of both Reiber’sI g Gr a t i o( Q IgG
=6 . 4 4 ;Q Alb = 6.66)[21] and Link’s IgG index (0.97).
Sustained, though markedly reduced, intrathecal produc-
tion of both total IgG and the PC-specific antibody was
demonstrated in a paired follow-up sample obtained two
months after commencement of corticosteroid therapy
(Table 1).
The antibody belongs to the IgG1 subclass and activates
complement in vitro
The antibody belonged mainly to the IgG1 subclass both
in the CSF and in the serum with only very weak stain-
ing for IgG3 and IgA (Figure 6). In line with this find-
ing, use of fresh human serum as complement source
resulted in C3b deposition with a distribution highly
similar to that of the IgG1 antibodies (Figure 6), indicat-
ing complement activation by the patient’s antibody. No
IgM, IgG2, or IgG4 antibodies to PCs were detectable in
CSF and serum.
The antibody recognizes a 80-97 kDa protein
A distinct single band between 80 kDa and 97 kDa was
detected when the initial CSF sample taken five days
after onset was tested using a commercial western blot
of primate total cerebellum extract. The same single
band was present in a follow-up CSF sample obtained
two months after onset of symptoms (Figure 7). Serum
analysis demonstrated a corresponding band at the same
position.
The antibody targets an antigen sited at the plasma
membrane and in the cytoplasm of Purkinje cells
Immunohistochemistry demonstrated binding of IgG
from the patient’s CSF to the cytoplasm of PC somata
(Figure 2) as well as to the plasma membrane of PC
dendrites and PC axons (Figure 8 and 9). No nuclear
staining (except for coilin in the serum but not CSF; see
below) was detectable (Figure 10). However,
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ing to cultured PCs, indicating that the antigen is not a
trans-membrane protein but rather located at the inner
side of the membrane (Figure 9). In contrast, fixation
and permeabilization was not required for membrane
binding in the IHC assay, most likely due to most PCs
having being transected during preparation of the 4-7
μm cryosections. This is important for potential future
diagnostic applications, since it allows testing for anti-
Ca on the same unfixed tissue sections that are already
used for the detection of most previously described anti-
cerebellar antibodies by indirect immunofluorescence.
Evidence for additional serum antibodies
While serum showed additional reactivity to capillaries
in the ML and the WM, no such binding was found
with CSF (Figure 2). The endothelial signal but not the
PC staining disappeared after preadsorption with guinea
pig liver powder (not shown). In addition, a fine punc-
tate staining in the nuclei (nuclear dots) was found only
with serum but not with CSF (Figure 10). However, no
such fluorescence was present when the serum samples
were tested at higher dilution, though the PC-specific
fluorescence was still clearly detectable. Double labeling
experiments identified the nuclear dot pattern found on
brain cells as p80-coilin antibodies (Figure 10). Binding
of the patient’s serum to human full length coilin pro-
tein was also found in the protein microarray assay
(median fluorescence units [FU] at 635 nm, 15676; med-
ian fluorescence of all proteins, 181; F-score, 10.62703;
F-score cut-off, 3). Furthermore, serum antibodies to
SS-A/Ro52 were detected, though no clinical signs of
connective tissue disorders, such as Sjoegren syndrome
or systemic lupus erythematodes, or of myositis were
present in the patient, and no further extractable
nuclear antigens such as nRNP/Sm, Sm, and SS-A/Ro-
60, SS-B, Scl-70, PM-Scl, Jo-1, PCNA, double stranded
DNA (dsDNA), centromer protein B (CEPB), nucleo-
somes, histones, and ribosomale P proteins were
detectable.
Figure 2 Binding of CSF IgG to the molecular layer (ML), the Purkinje cell layer (PCL) and the white matter (WM) on a mouse
cerebellum tissue section. An AlexaFluor® 488 labeled goat anti-human IgG antibody was used to visualize bound patient IgG. GL = granular
layer, P = pia mater.
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Using two independent commercial line blot assays and
a cerebellum western blot assay for the detection of
classical paraneoplastic antibodies, no evidence was
found for anti-Hu, anti-Ri, anti-Yo, anti-Ma, anti-Ta,
anti-CV2/CRMP5, or anti-amphiphysin. Moreover, the
PC-specific staining pattern found in our study did not
correspond to the typical fluorescence patterns of any of
those antibodies as described in the previous literature,
or to that of ANNA-3[13], PCA-2[12], or anti-Tr[7,25].
Antibodies to Homer3[20], PKCg [9], mGluR1[11,26],
and GluRδ2[18,19], which were described in occasional
patients with subacute cerebellar degeneration, and
which are known to bind to PC somata and/or den-
drites, and antibodies to GluR3 were ruled out by wes-
tern blot analysis (Figure 7) and by double labeling
experiments employing mouse and rat cerebellum tissue
sections (Figure 1112). Antibodies to VGCC, which are
a rare cause of ataxia, were excluded in a commercial
radioimmunoprecipitation assay (Euroimmun).
Figure 3 Double labeling with an antibody to calbindin, a specific marker of Purkinje cells (PCs), proved that the cellular structures
targeted by the patient’s CSF IgG correspond to PC somata, PC dendrites (upper panel), and PC axons (lower panel). Anti-calbindin
reactivity is depicted in red (AlexaFluor® 568); the patient’s antibody in green (AlexaFluor® 488); and yellow color indicates overlay of the two
antibodies. Nuclei are shown in blue (DAPI). Note that the patient’s antibody spared the PC nucleus.
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demonstrated by double staining with an antibody to anti-glial fibrillary acidic protein (GFAP). The anti-GFAP antibody, staining
astrocytes in the granular layer (GL) as well as the processes of the BGCs in the molecular layer (ML) and along the pia mater (P), is depicted in
red (AF568); and the patient’s antibody is labeled in green (AF488); yellow color would indicate overlay of the two antibodies, but is absent.
Nuclei are shown in blue.
Figure 5 Double staining of the cerebellar cortex with an antibody to parvalbumin (green; AF488), a general marker of cerebellar
neurons, demonstrates that the patient’s antibody (red; AF568) binds neither to interneurons (arrow heads) in the molecular layer
(ML) nor to granular cells in the granular layer.
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Page 8 of 19Table 1 Laboratory findings, treatment, and treatment response over the course of disease
Months
from onset
Cells/
μl
CSF
Total
protein
mg/dl
IgG
anti-
Ca
titers
(IHC)
QIgG
anti-
Ca
IgG
total
mg/
dl
QIgG IgM
total
mg/
dl
QIgM Albumin
total
mg/dl
QAlb Qlim AI
anti-
Ca
OCBs
CSF/
serum
CSF Serum CSF Serum CSF Serum CSF Serum
04 4 ↑ 48 ↑ 1:2000 1:6000 333.3 7.66 1190 6.44 0.567 267 2.12 25.1 3770 6.66 4.89 68.2 Pos/
neg
Interventions: 3 × 1000 mg methylprednisolone (MP) intravenously followed by oral therapy over 3 weeks at an initial dose of 60 mg MP, resulting in
marked neurological improvement. After tapering corticosteroids to 12.5 mg MP per day the patient experienced worsening of symptoms
together with an exaggerated startle response (month 2).
2 1 31 N.d. N.d. N.d. 3 813 3.69 0.086 296 0.29 10.4 4410 2.36 1.46 N.d. N.d.
Interventions: 5 × 500 mg methylprednisolone (MP) intravenously (month 3) and 5 × 500 mg methylprednisolone (MP) intravenously + intravenous
immunoglobulins (month 4), followed by only slight and transient neurological improvement. Oral therapy with MP at an initial dose of
60 mg MP.
5 2 25 1:200 1:7000 28.6 1.9 927 2.05 0.065 251 0.26 14.7 3950 3.72 2.44 11.7 Pos/
neg
Interventions: Plasma exchange at month 6 (after progressive neurological deterioration), followed by clinical stabilization and moderate improvement.
AI = antibody index (see method section for details); CSF = cerebrospinal fluid; IHC = immunohistochemistry; QIgG = IgG CSF/serum ratio; QIgM = IgM CSF/serum
ratio; QAlb = albumin CSF/serum ratio; Qlim = upper reference range for IgG, albumin-dependent (see method section for details); OCB = oligoclonal bands.
Figure 6 Subclass analysis revealed that the antibody belongs mainly to the IgG1 subclass (panel A). In addition, antibodies of the IgA
subclass were detectable (panel B). In line with the presence of IgG1 antibodies, fixing of complement C3b was found (panel C; the two upper
images show negative control experiments with an isotype control and without complement, respectively). Only very weak IgG3 reactivity and
no IgG2, IgG4, or IgM antibodies were detectable in serum or CSF (not shown).
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Page 9 of 19Antibodies to NMDA receptors (subunit NR1a and
NR2b) and AMPA receptors (subunits GluR1 and
GluR2) were ruled out by indirect immunofluorescence
on primate hippocampus tissue sections and by use of a
cell-based assay employing HEK cells transfected with
the respective antigens (Euroimmun). Commercial
immunoblot assays revealed no evidence for ganglioside
antibodies to GM1, GM2, GM3, GD1a, GD1b, GT1b, or
GQ1b; antibodies against deaminated gliadin and anti-
bodies to tissue transglutaminase were negative as well.
Homer-3, PKCg, Zic4, GAD, amphiphysin, and GluR2
were included also in the protein microarray, but were
not recognized by the patient’s IgG.
Co-localization with the inositol-3-phosphate receptor
type I
On cerebellum sections, we found an almost perfect
overlay of the staining pattern found with the patient
antibody in the molecular layer and that found with a
commercial antibody to the inositol-3-phosphate recep-
tor type I (IPR3I) (Figure 13A-C and 13D), which was
used as a well established marker of PCs. However, an
only partial overlay was found in the white matter (Fig-
ure 13E-F), indicating that the patient antibody targets
an antigen that is spatially closely associated with IP3RI
in some parts of the cerebellum but not identical to
IP3RI. Accordingly, no band corresponding to the mole-
cular weight of IP3RI (~300 kDa) was found by western
blotting. Moreover, dot blot assays with three different
IP3RI peptides (Santa Cruz) and a partial recombinant
IP3RI protein (Abnova) were negative (not shown).
Identification of ARHGAP26 as the target antigen
Probing of a commercial protein microarray containing
>9000 human full-length proteins revealed strong bind-
ing of the patient’s serum to Rho GTPase activating pro-
tein 26 (ARHGAP26; alternative designations include
GTPase regulator associated with focal adhesion kinase
pp125, GRAF, and oligophrenin-1-like protein) (median
fluorescence units [FU] at 635 nm, 55323; median FU of
all proteins, 181; F-score, 38.7627; F-score cut-off, 3)
(Figure 14A). In line with this finding, IgG from the
Figure 7 A commercial western blot of primate cerebellum extract revealed binding of CSF IgG to a 80-97 kDa band, which does not
correspond to bands found with antibodies to inositol-triphosphate receptor type I (IP3RI), protein kinase C gamma (PKCg),
glutamate receptor delta 2 (GluRδ2), metabotropic glutamate receptor 1a (mGluR1a), or Homer3.
Jarius et al. Journal of Neuroinflammation 2010, 7:21
http://www.jneuroinflammation.com/content/7/1/21
Page 10 of 19patient’s serum (lane 1; increasing protein dilutions from
b o t t o mo ft o p )b u tn o tf r o mh e a l t h yc o n t r o l s( l a n e2 - 4 )
bound also to commercially available recombinant
human full length ARHGAP26 from another manufac-
turer in a dot blot assay (Figure 14B). Accordingly,
probing of a western blot of primate cerebellum extract
with the patient’s CSF revealed binding of IgG to a band
running at the same height as a band detected with a
commercial antibody to ARHGAP26 (Figure 14C). The
same commercial ARHGAP26 antibody bound to the
Purkinje cell layer and the molecular layer in an immu-
nofluorescence assay and displayed overlay with the
patient’s IgG (Figure 14D-E). Finally, preadsorption of
the patient’s CSF with human ARHGAP26 protein but
not preadsorption with control proteins resulted in
complete loss of binding to cerebellum tissue sections
(Figure 14F-H).
Discussion
We identified a new serum and CSF autoantibody to
Purkinje cells (PCs) in a patient with subacute cerebellar
ataxia. Further experiments revealed ARHGAP26 as its
target antigen. Our findings expand the panel of diag-
nostic serum markers of autoimmune ataxia and suggest
a role of ARHGAP26 autoimmunity in the pathogenesis
of this condition.
Autoantibody-associated subacute cerebellar ataxia is
frequently of paraneoplastic nature[1,2]. Despite broad
diagnostics, including repeat FDG-PET-CT scans, no
tumor has been found in our patient 17 months after
onset. However, paraneoplastic antibodies and the asso-
ciated syndromes can precede tumor diagnosis by sev-
eral years. In a large study on patients with anti-Yo
antibodies, the most common paraneoplastic serum
reactivity associated with autoimmune cerebellar ataxia,
the neurologic syndrome preceded the diagnosis of can-
cer by up to 15 months and in many led to that diagno-
sis[4]. We can therefore not yet completely exclude a
paraneoplastic origin of the syndrome.
Ataxia developed two weeks after a common cold in
our patient. The close temporal relationship could indi-
cate a causal link between the two events. Molecular
mimicry has indeed been discussed to play a role in the
pathogenesis of other autoimmune disorders of the ner-
vous system such as the Guillain Barré syndrome[27].
Alternatively, infections can operate as a disease trigger
in autoimmune disease[28]. Viral infections are well
known to prompt disease activity in MS, and antecedent
signs of viral infections were reported in 15-35% of neu-
romyelitis optica cases[29,30]. However, given the high
prevalence of viral infections, the two events might well
be causally unrelated.
Figure 8 High magnification revealed binding of IgG from the patient’s CSF to membranes of PC dendrites and axons. Panel A shows
transverse sections and panel B depicts longitudinal sections of distal PC dendrites (mouse tissue). Panel C shows three longitudinal sections of
proximal PC dendrites (monkey tissue). Panel D consists of a composite of transverse and longitudinal sections of monkey PC axons. A goat anti-
human IgG antibody labeled with AF488 was used to visualize bound IgG.
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Page 11 of 19Figure 9 Double staining of cultured Purkinje cells (PC) with the patient’s serum revealed binding of IgG to PC somata and to
membranes of PC dendrites and axons. Calbindin is depicted in green (A; AF488); the patient’s antibody in red (B; AF555); yellow color
indicates overlay of the two antibodies (C). Binding was only observed after fixation with 4% paraformaldehyde and 0.05% triton-X (A-C), but not
on living cells (D-E), suggesting an intracellular localization of the target antigen. Panel D shows fluorescence of a GFP-transfected living (i.e.
unfixed) PC; Panel E demonstrates lack of binding of the patient’ serum to the same cell.
Figure 10 Double staining of cerebellum tissue sections with a commercial antibody to p80-coilin identifies the dotted nuclear
staining seen with the broad majority of cerebellar neurons following incubation with the patient’s serum (but not CSF) as anti-coilin
immunoreactivity. The patient’s antibody is depicted in green (A; AF488); the commercial coilin antibody in red (B; AF568); yellow color
indicates overlay of the two antibodies (C). The p80-coilin antibody recognized a ~80 kDa protein band (lane 1) in a western blot of primate
cerebellum tissue, which was not identical to the 80-97 kDa band found with the patient’s serum and CSF (lane 2).
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Page 12 of 19The antibody bound almost exclusively to PCs. In
good agreement with this finding, MRI and PET-CT
did not display any sites of inflammation outside the
cerebellum. However, it is of notice that our patient
developed an increased sta r t l er e s p o n s ea n dab r i s k
head retraction reflex two months after onset, sugges-
tive of symptomatic hyperekplexia, a condition mainly
found in patients with brain stem disease[31]. More-
over, severe depression, restlessness, and anxiety
occurred in our patient, which could indicate an invol-
vement of the limbic system. We can therefore not
completely rule out that other areas of the CNS were
affected as well. On the other hand, rare cases of sec-
ondary hyperekplexia due to cerebellar pathology have
indeed been reported in the literature[32], and a com-
bination of steroid-induced and reactive depression
sufficiently explains the patient’s psychiatric
symptoms.
Figure 11 No evidence for antibodies to Homer3 (A) or the metabotropic glutamate receptor 1 alpha (mGluR1a)( B )i nt h ep a t i e n t ’s
CSF as demonstrated by double staining with commercial antibodies to these antigens. While the patient’s CSF preferentially stained
Purkinje cell dendrites on mouse (Panel A and B) and monkey (Panel A, inset) tissue, Homer3 and mGluR1a immunoreactivity was widely
restricted to dendritic spines. IgG antibodies to Homer3 and mGluR1a are depicted in red (AF568); the patient’s IgG is labeled in green; yellow
color indicates overlay of the two antibodies. Nuclei are shown in blue (DAPI).
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Page 13 of 19Figure 12 No evidence for antibodies to the glutamate receptor delta 2 (GluRδ2) (A) or the protein kinase C type gamma (PKCg) (B) in
the patient’s CSF as demonstrated by double staining with commercial antibodies to these antigens. Note that the anti-GluRδ2 antibody
as well as the anti-PKCg antibody stained interneurons on mouse (A and B; arrows) and primate (B, left upper inset; arrows) cerebellar tissue,
which were spared by the patient’s antibody (cf. Figure 5). The anti-PKCg antibody also bound to dendritic spines on monkey tissue that were
not stained by the patient’s antibody (B, right upper inset). In contrast to the patient’s CSF, anti-PKCg stained capillaries in primate brain (asterisk).
Moreover, the cytoplasmic staining found with the anti-PKCg antibody exceeded that caused by the patient’s antibody and appeared to include
the nuclear membrane (B, lower inset; left and right images represent different exposure times). IgG antibodies to GluRδ2 and PKCg are depicted
in red (AF568); the patient’s IgG is labeled in green; yellow color indicates overlay of the two antibodies. Nuclei are shown in blue (DAPI).
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Page 14 of 19Figure 13 Double labeling of a primate cerebellum tissue section with a commercial antibody to inositol-triphosphate receptor I
(IP3RI), depicted in red (AF568), and the patient’s CSF, shown in green (AF488). Nuclei are shown in blue (DAPI). An almost perfect
overlay (yellow) of the two antibodies was found in the molecular layer and the Purkinje cell (PC) layer (Panels A-C), indicating that the patient’s
antibody targets an antigen expressed in close spatial proximity of IP3RI. Higher magnification (40×; D) suggests that the two antibodies might
also bind to dendritic spines of PCs, though not all spines were stained by both antibodies. A fair, though less impressive, overlay was found in
the white matter, where the two antibodies stained the same axons (E-G).
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Page 15 of 19T h e r ei ss o m ee v i d e n c ef o rad i r e c tr o l eo ft h ea n t i -
body in the pathogenesis of the condition. First, the
a n t i b o d yi sh i g h l ys p e c i f i cf o rP C s .P C sa r eG A B A e r g i c
neurons located in the cerebellar cortex and constitute
the only output of motor coordination from the cerebel-
lar cortex. Secondly, the antibody is produced intrathe-
cally and at high titers. We found an extraordinarily
high antibody index (AI) at onset (Table 1), strongly
indicating that it is produced by clonally expanded B
cells within the CNS[21]. Thirdly, it belongs to the IgG1
subclass and is capable of initiating complement C3b
deposition in vitro, suggesting that it may act on PCs
via complement-dependent mechanisms. Antibody-
induced complement-mediated cytotoxicity is a well
established feature in other autoantibody-associated
disorders with presumed humoral pathogenesis such as
neuromyelitis optica[33,34], though other direct effects
such as antibody-dependent cell-mediated cytotoxicity
or induction of apoptosis might have played a role as
well. Finally, plasma exchange (PEx) and immunoad-
sorption (IA) was followed by clinical stabilization and
moderate improvement. Unfortunately, no CSF or
serum samples obtained shortly after PEx/IA were avail-
able for analysis. Testing of a paired CSF and serum
sample taken after treatment with intravenous methyl-
prednisolone and IVIG showed a decline of the Purkinje
cell antibody index (AI) from 68 at month 1 to 12 at
month 6, and normalization of the cell count and the
blood brain barrier function. Interestingly, however, the
decline of the AI value was mainly due to a decrease of
Figure 14 Probing of a commercial protein microarray revealed strong binding of the patient’s sera to human ARHGAP26 (Panel A).I n
accordance with this finding, binding of IgG from the patient’s serum (Lane P), but not from three healthy controls (Lane C1-C3), to a
recombinant human full length ARHGAP26 protein was found (Panel B). Western blotting confirmed the presence of ARHGAP26 in primate
cerebellar extract (Panel C, lane 2), and incubation with the patient’s CSF resulted in a band running at the same height as the ARHGAP26 band
(Panel C, lane 1); the significance of the additional band recognized by the commercial antibody is unknown. The commercial ARHGAP26
antibody bound to the Purkinje cell layer and the molecular layer (Panel D) and showed a good overlay with the patient’s IgG depicted in
yellow (Panel E). Finally, preadsorption of the patient’s CSF with the ARHGAP26 protein (Panel H), but not preadsorption with a control protein
(Panel G), resulted in complete loss of binding to cerebellar tissue sections in an indirect immunofluorescence assay; panel F shows binding of
IgG from a non-preadsorbed aliquot of the same CSF sample (exposure time was 2 sec in all cases to detect also low fluorescence signals).
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Page 16 of 19the CSF titer from 1:2000 to 1:200, while the serum titer
of the antibody did not change significantly.
However, passive transfer experiments, which alone
could prove a direct pathogenic effect of the antibody,
have not yet been performed. We can therefore not fully
exclude that the antibody represents only an epipheno-
menon, similar to the situation in many paraneoplastic
neurological diseases, while the actual tissue damage is
caused by other components of the immune system
such as T cells. Indeed, the antibody targets a protein
that resides at the inner side of the plasma membrane
and in the cytoplasm. This is important since some
authors believe that intracellular antigens might not be
accessible to antibodies in vivo. Most neurological auto-
antibodies of proven pathogenic impact, such as antibo-
dies to AQP4 in neuromyelitis optica [34-36],
acetylcholine receptor in myasthenia gravis, VGCC in
Lambert Eaton syndrome[37], and mGluR1 in paraneo-
plastic cerebellar degeneration[10] in fact target trans-
membrane proteins. Moreover, passive transfer of
antibodies to nuclear antigens such as anti-Yo [38-40]
have not produced clinical disease in animal studies.
Instead, T cell-mediated immune mechanisms directed
against the target antigen of the accompanying antibody
have been proposed to play a role in those disorders
[41-44].
However, there is still little direct evidence for a major
role of T cells. Moreover, there are conditions in which
antibodies against intracellular antigens were indeed
shown to be of pathogenic impact, as proven by passive
transfer. Sommer et al. found dose-dependent stiffness
with spasms resembling human stiff-person syndrome in
rats after injection of human serum containing high
titers of antibodies to amphiphysin, a protein associated
with the cytoplasmic surface of synaptic vesicles[45].
Interestingly, both amphiphysin and ARHGAP26 are
involved in endocytosis[46]. One of the main roles of
amphiphysin is to recruit dynamin to sites of clathrin-
mediated endocytosis in GABAergic neurons[47]. Dyna-
min, a protein with GTPase activity, is important also in
the clathrin-independent endocytic pathway, which is
regulated by ARHGAP26[46], and ARHGAP26 is a
strong interactor of dynamin[46]. Both proteins, amphi-
physin and ARHGAP26, contain a BAR domain and a
SH3 domain, though cross-reactivity of the patient’s
antibody with amphiphysin was excluded in our study
by three independent methods (protein microarray;
commercial line blot; and IHC). The patient’sI g G
indeed precipitated ARHGAP26 and co-precipitated
dynamin from a mouse cerebellar extract as demon-
strated by mass spectroscopy (data not shown), which is
in perfect accordance with a recent study reporting co-
precipitation of dynamin from rat brain cytosol by a
non-human, ARHGAP26-specific antibody[46]. Besides
anti-amphiphysin, a direct pathogenic effect of antibo-
dies on intracellular proteins has also been shown for
recoverin, which is located inside of retinal cells[48].
Anti-recoverin antibodies were demonstrated to enter
retinal cells actively, probably by endocytosis, and
uptake of anti-recoverin (but not of control IgG)
induced caspase-dependent apoptosis[48]. Endocytotic
uptake of antibodies has also been shown for a subset of
anti-DNA antibodies [49-51]. Finally, a recent study
demonstrated that PCs incorporate immunoglobulins of
both the IgG and the IgM classes in vitro, independent
of the immunoglobulin’s reactivity with Purkinje cell
surface antigens, giving raise to speculation as to
whether paraneoplastic or other autoantibodies reactive
with cytoplasmic or nuclear Purkinje cells antigens
might be taken up intracellularly and could potentially
produce cell injury and death[52].
ARHGAP26 has not previously been described as an
autoimmune target in human or animal disease. How-
ever, mutations of ARHGAP26 are a rare cause of juve-
nile myelomonocytic leukemia[53], one of the most
common pediatric myelodysplastic syndromes.
Further research is now needed to evaluate the exact
role of anti-ARHGAP26 antibodies in the pathogenesis
of cerebellar ataxia, involving the development of a pas-
sive transfer animal model. Moreover, diagnostic tests
are to be developed to assess the frequency of anti-
ARHGAP26 antibodies in patients with subacute ataxia.
Conclusion
We describe a new autoantibody to Purkinje cell
somata, dendrites and axons associated with subacute
cerebellitis. The antibody targets ARHGAP26 and is
produced intrathecally. Our findings indicate a role of
autoimmunity to ARHGAP26 in the pathogenesis of
subacute inflammatory cerebellar ataxia and expand the
panel of diagnostic markers for this devastating
condition.
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